Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Jun 15;62(12):1514-1520.
doi: 10.1093/cid/ciw173. Epub 2016 Apr 3.

Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?

Bhavarth S Shukla  1   2 , Samuel Shelburne  2   3 , Katherine Reyes  4 , Mini Kamboj  5 , Jessica D Lewis  6 , Sandra L Rincon  1   7 , Jinnethe Reyes  7 , Lina P Carvajal  7 , Diana Panesso  1   7 , Costi D Sifri  6 , Marcus J Zervos  4   8 , Eric G Pamer  5 , Truc T Tran  1 , Javier Adachi  2 , Jose M Munita  1   9 , Rodrigo Hasbun  1 , Cesar A Arias  1   7
Affiliations
Multicenter Study

Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?

Bhavarth S Shukla et al. Clin Infect Dis. .

Abstract

Background: Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faecium bloodstream infections (BSIs). We previously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in the higher end of susceptibility frequently harbor mutations associated with daptomycin resistance. We postulate that patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 µg/mL treated with daptomycin are more likely to have worse clinical outcomes than those exhibiting daptomycin MICs ≤2 µg/mL.

Methods: We conducted a multicenter retrospective cohort study that included adult patients with E. faecium BSI for whom initial isolates, follow-up blood culture data, and daptomycin administration data were available. A central laboratory performed standardized daptomycin MIC testing for all isolates. The primary outcome was microbiologic failure, defined as clearance of bacteremia ≥4 days after the index blood culture. The secondary outcome was all-cause in-hospital mortality.

Results: A total of 62 patients were included. Thirty-one patients were infected with isolates that exhibited daptomycin MICs of 3-4 µg/mL. Overall, 34 patients had microbiologic failure and 25 died during hospitalization. In a multivariate logistic regression model, daptomycin MICs of 3-4 µg/mL (odds ratio [OR], 4.7 [1.37-16.12]; P = .014) and immunosuppression (OR, 5.32 [1.20-23.54]; P = .028) were significantly associated with microbiologic failure. Initial daptomycin dose of ≥8 mg/kg was not significantly associated with evaluated outcomes.

Conclusions: Daptomycin MICs of 3-4 µg/mL in the initial E. faecium blood isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be considered.

Keywords: E. faecium; MIC; bloodstream infection; daptomycin; resistance.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Methodology for application of exclusion criteria. Abbreviations: BSI, bloodstream infection; E. faecium, Enterococcus faecium.
See this image and copyright information in PMC

References

    1. Hidron A, Edwards JR, Patel J et al. . NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008; 29:996–1011. - PubMed
    1. Magill SS, Edwards JR, Bamberg W et al. . Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198–208. - PMC - PubMed
    1. Clewell DB, Gawron-Burke C. Conjugative transposons and the dissemination of antibiotic resistance in streptococci. Annu Rev Microbiol 1986; 40:635–59. - PubMed
    1. Wells VD, Wong ES, Murray BE, Coudron PE, Williams DS, Markowitz SM. Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med 1992; 116:285–92. - PubMed
    1. Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS, Schaberg DR. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med 1987; 106:687–91. - PubMed

Publication types

MeSH terms